The Six-Minute Walking Test (6WT) and Timed-Up-and-Go (TUG) Test as Measures of Objective Functional Impairment in Patients Undergoing Interlaminar or Transforaminal Epidural Steroid Injection for Lumbar Degenerative Disc Disease (DDD)

Cantonal Hospital of St. Gallen50 enrolled

Overview

The primary objective is to determine the validity of the Six-Minute-Walking Test (6WT) and Timed-Up and Go (TUG) test to measure objective functional impairment (OFI) in patients undergoing either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) for lumbar degenerative disc disease (DDD)

The purposes of the project are to assess the ability of the Six-Minute-Walking Test (6WT) and Timed-Up and Go (TUG) test to measure and classify the disease burden, and to determine their relation to already established subjective patient reported outcome measures (PROMs)in patients treated with either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) for lumbar degenerative disc disease (DDD). No research has so far determined its validity to determine OFI in a cohort of patients managed conservatively. We want to use an existing smartphone-applications for the 6WT and TUG test. Applying self-measurement of the 6WT within the context of a two center observational study will determine OFI in patients before and after (TF)ESI. The results of this study add to the understanding of achievable objective outcomes after steroid injection applied to patients with DDD.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lumbar Disc Disease Lumbar Spine Degeneration Lumbar Spinal Stenosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with symptomatic lumbar Degenerate Disc Disease (DDD), scheduled for either either interlaminar epidural steroid injection (ESI) or transforaminal epidural steroid injections (TFESI) * Male and Female subjects ≥ 18 years * Written informed consent Exclusion Criteria: * Pregnancy * Inability to walk (extreme pain or severe neurological deficits) * Severe Chronic Obstructive Lung Disease (COPD) corresponding to ≥ Gold III * Severe heart failure corresponding to ≥ New York Heart Association (NYHA) III * Lung cancer and diffuse parenchymal lung disease * Other medical reasons interfering with the patient's ability to walk and perform the 6WT/TUG (e.g., osteoarthritis disease of the lower extremities, Parkinson's disease, heart failure, hip or knee prosthesis etc.) * Unavailability for follow up and/or inability to complete assessment (planning to move, no smartphone, etc.).

Locations (2)

Kantonsspital St. Gallen / Department of Neurosurgery

Sankt Gallen, Switzerland

University Hospital Zürich / Department of Neurosurgery

Zurich, Switzerland

Outcomes

Primary Outcomes

Raw Walking distance

The difference in 6WD (in m), as measured with the 6WT, between the baseline (before injection) and 4-week (range 2-6 weeks) follow-up assessment (after injection).

Time frame: 2-6 weeks

Secondary Outcomes

Raw Walking distance - day 1

Difference in Six-minute-walking test (6WD, in m) between baseline and 1-day follow-up

Time frame: 1 day

Raw Walking distance - day 7

Difference in 6WD (in m) between baseline and 7-day follow-up

Time frame: 7 days

TTFS and DTFS - day 1

Difference in Time to first symptoms (TTFS, in sec) and Distance to First Symptoms (DTFS, in m), as measured by the 6WT, between the baseline and 1-day follow-up assessment

Time frame: 1 day

TTFS and DTFS - day 7

Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 7-days follow-up assessment

Time frame: 7 days

TTFS and DTFS - 4 weeks

Difference in TTFS and DTFS, as measured by the 6WT, between the baseline and 4 weeks follow-up assessment

Time frame: 4 weeks

ODI

Difference in PROM, as measured by the Oswestry Disability Index (ODI score, range 0% (best) - 100% (worst)), between the baseline- and 4-week follow-up assessment

Time frame: 4 weeks

COMI

Difference in PROM, as measured by the Core Outcome Measure Index (COMI score, range 0 (best) - 10 (worst)), between the baseline- and 4-week follow-up assessment

Time frame: 4 weeks

SF -12

Difference in in health-related quality of life (hrQoL), as measured by the SF-12 score (SF-12 score, range 0 (worst) - 1 (best)), between the baseline- and 4-week follow-up assessment

Time frame: 4 weeks

NRS Pain

Difference in pain intensity, as measured by the NRS pain scale (NRS pain score, range 0 (best) - 10 (worst)), between the baseline- and 1-day, 7-day and 4-week follow-up assess-ments

Time frame: up to 4 weeks

Correlation 6WD/ODI

Correlation of 6WD with the ODI score at baseline and 4-week follow up

Time frame: 4 weeks

Correlation 6WD/COMI

Correlation of 6WD with the COMI score at baseline and 4-week follow up

Time frame: 4 weeks

Correlation 6WD/SF-12

Correlation of 6WD with the SF-12 score at baseline and 4-week follow up

Time frame: 4 weeks

Correlation 6WD/NRS Pain

Correlation of 6WD with the NRS pain score at baseline and 1-day, 7-days and 4-week follow up

Time frame: up to 4 weeks

Correlation 6WD/TUG

Correlation of 6WD with the TUG test at baseline and 4-week follow up

Time frame: 4 weeks

TUG T-Score

Difference in TUG T-score between the baseline (before injection) and 4-week follow-up assessment (after injection)

Time frame: 4 weeks

Correlations TUG/PROMS

Correlation of TUG T-score with the ODI/COMI/NRS Pain/SF-12 score at baseline and follow up

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.